Lineage Cell Therapeutics (LCTX) Equity Income (2015 - 2024)

Lineage Cell Therapeutics (LCTX) posted quarterly Equity Income of -$4000.0 for Q2 2024, up 82.61% quarter-over-quarter from -$23000.0 in Q3 2023.

Lineage Cell Therapeutics (LCTX) Equity Income (2015 - 2024) Analysis & Trends

Lineage Cell Therapeutics' Equity Income history runs 10 years deep, the most recent figure standing at -$4000.0 for Q2 2024.

In Q2 2024, Equity Income changed N/A year-over-year to -$4000.0; the TTM figure through Mar 2025 stood at -$4000.0 (up 82.61% YoY), while the FY2024 annual figure was -$4000.0, up 82.61% from the prior year.
Equity Income for Q2 2024 stood at -$4000.0, up from -$23000.0 in the prior quarter.
The five-year high for Equity Income was $3.7 million in Q4 2020, with the low at -$4.1 million in Q2 2020.
The 5-year median for Equity Income is -$375000.0 (2022), against an average of -$494571.4.
The sharpest annual moves came in 2021 and 2022: Equity Income surged 114.23% in 2021, then slumped 220.17% in 2022.
Lineage Cell Therapeutics' Equity Income stood at $3.7 million in 2020, then tumbled by 145.29% to -$1.7 million in 2021, then soared by 69.19% to -$517000.0 in 2022, then jumped by 95.55% to -$23000.0 in 2023, then jumped by 82.61% to -$4000.0 in 2024.
Business Quant data shows LCTX's Equity Income at -$4000.0 in Q2 2024, -$23000.0 in Q3 2023, and $40000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Lineage Cell Therapeutics	270.61 Mn	212.77 Mn	1.07 Mn	-

Download Data